{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:28:30Z","timestamp":1790980110887,"version":"4.1.0"},"publisher-location":"Cham","reference-count":55,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319442501","type":"print"},{"value":"9783319442518","type":"electronic"}],"license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"DOI":"10.1007\/5584_2016_97","type":"book-chapter","created":{"date-parts":[[2016,10,8]],"date-time":"2016-10-08T08:31:45Z","timestamp":1475915505000},"page":"117-127","source":"Crossref","is-referenced-by-count":14,"title":["Treatment of Hypertension: Which Goal for Which Patient?"],"prefix":"10.1007","author":[{"given":"Fai\u00e7al","family":"Jarraya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"97_CR1","doi-asserted-by":"publisher","unstructured":"[no authors listed] (1967) Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressure averaging 115 through 129mmhg. JAMA 202:1028\u20131034","DOI":"10.1001\/jama.1967.03130240070013"},{"key":"97_CR2","doi-asserted-by":"publisher","unstructured":"[no authors listed] (1970) Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114mmhg. JAMA 213:1143\u20131052","DOI":"10.1001\/jama.1970.03170330025003"},{"key":"97_CR3","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","volume":"362","author":"WC Cushman","year":"2010","unstructured":"ACCORD Study Group, Cushman WC, Evans GW, Byington RP et al (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362:1575\u20131585","journal-title":"N Engl J Med"},{"key":"97_CR4","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1053\/ajkd.2000.16225","volume":"36","author":"GL Bakris","year":"2000","unstructured":"Bakris GL, Williams M, Dworkin L et al (2000) Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 36:646\u2013661","journal-title":"Am J Kidney Dis"},{"key":"97_CR5","doi-asserted-by":"publisher","unstructured":"Beckett NS, Peters R, Fletcher AE, et al. for the HYVET Study Group (2008) Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358:1887\u20131898","DOI":"10.1056\/NEJMoa0801369"},{"key":"97_CR6","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.lpm.2013.01.022","volume":"42","author":"J Blacher","year":"2013","unstructured":"Blacher J, Halimi JM, Hanon O et al (2013) Prise en charge de l\u2019hypertension art\u00e9rielle de l\u2019adulte. Recommandations 2013\u00a0de la Soci\u00e9t\u00e9 fran\u00e7aise d\u2019hypertension art\u00e9rielle. Presse Med 42:819\u2013825","journal-title":"Presse Med"},{"key":"97_CR7","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S0140-6736(14)61212-5","volume":"384","author":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration","year":"2014","unstructured":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration (2014) Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet 384:591\u2013598","journal-title":"Lancet"},{"key":"97_CR8","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","volume":"289","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee et al (2003) The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289:2560\u20132572","journal-title":"JAMA"},{"key":"97_CR9","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/jch.12766","volume":"18","author":"DL Cohen","year":"2016","unstructured":"Cohen DL, Townsend RR (2016) Which patients does the SPRINT study not apply to and what are the appropriate blood pressure goals in these populations? J Clin Hypertens (Greenwich) 18:477\u2013478","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"97_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1001\/jama.2010.884","volume":"304","author":"RM Cooper-DeHoff","year":"2010","unstructured":"Cooper-DeHoff RM, Gong Y, Handberg EM et al (2010) Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 304:61\u201368","journal-title":"JAMA"},{"key":"97_CR11","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1161\/01.HYP.0000170138.56903.7a","volume":"46","author":"E Dolan","year":"2005","unstructured":"Dolan E, Stanton A, Thijs L et al (2005) Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 46:156\u2013161","journal-title":"Hypertension"},{"issue":"3 Suppl 2","key":"97_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1524-6175.2003.02463.x","volume":"5","author":"WJ Elliott","year":"2003","unstructured":"Elliott WJ (2003) The economic impact of hypertension. J Clin Hypertens (Greenwich) 5(3 Suppl 2):3\u201313","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"97_CR13","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1097\/HJH.0b013e3282f0580f","volume":"25","author":"ESH-ESC Task Force on the Management of Arterial Hypertension","year":"2007","unstructured":"ESH-ESC Task Force on the Management of Arterial Hypertension (2007) Guidelines 2007 ESH-ESC practice guidelines for the management of arterial hypertension. J Hypertens 25:1751\u20131762","journal-title":"J Hypertens"},{"key":"97_CR14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1056\/NEJMoa021778","volume":"348","author":"P Gaede","year":"2003","unstructured":"Gaede P, Vedel P, Larsen N et al (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383\u2013393","journal-title":"N Engl J Med"},{"key":"97_CR15","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMoa0706245","volume":"358","author":"P Gaede","year":"2008","unstructured":"Gaede P, Lund-Andersen H, Parving HH et al (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580\u2013591","journal-title":"N Engl J Med"},{"key":"97_CR16","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(15)00128-2","volume":"386","author":"GBD 2013 Risk Factors Collaborators","year":"2015","unstructured":"GBD 2013 Risk Factors Collaborators (2015) Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386:2287\u20132323","journal-title":"Lancet"},{"key":"97_CR17","unstructured":"Hajem S, Hsairi M (2013) Le syst\u00e8me national d\u2019information sur les causes de d\u00e9c\u00e8s: Diagnostic de situation et principaux r\u00e9sultats. National Institute of Public Health, Ministry of Heath, Tunisia"},{"key":"97_CR18","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","volume":"351","author":"L Hansson","year":"1998","unstructured":"Hansson L, Zanchetti A, Carruthers SG et al (1998) Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351:1755\u20131762","journal-title":"Lancet"},{"key":"97_CR55","unstructured":"Jarraya F, Lakhdar R, Kammoun K et al (2013) Microalbuminuria: a useful marker of cardiovascular disease. Iran J Kidney Dis 7:178\u201386"},{"key":"97_CR19","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","volume":"363","author":"S Julius","year":"2004","unstructured":"Julius S, Kjeldsen SE, Weber M et al (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 363:2022\u20132031","journal-title":"Lancet"},{"key":"97_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.7326\/0003-4819-55-1-33","volume":"55","author":"WB Kannel","year":"1961","unstructured":"Kannel WB, Dawber TR, Kagan A et al (1961) Factors of risk in the development of coronary heart disease\u2013six year follow-up experience. The Framingham Study. Ann Intern Med 55:33\u201350","journal-title":"Ann Intern Med"},{"key":"97_CR21","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group (2012) KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int (Suppl.) 2:337\u2013414"},{"key":"97_CR22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3109\/08037051.2015.1130775","volume":"25","author":"SE Kjeldsen","year":"2016","unstructured":"Kjeldsen SE, Narkiewicz K, Hedner T et al (2016a) The SPRINT study: outcome may be driven by difference in diuretic treatment demasking heart failure and study design may support systolic blood pressure target below 140 mmHg rather than below 120 mmHg. Blood Press 25:63\u201366","journal-title":"Blood Press"},{"key":"97_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3109\/08037051.2015.1106750","volume":"25","author":"SE Kjeldsen","year":"2016","unstructured":"Kjeldsen SE, Berge E, Bangalore S et al (2016b) No evidence for J-shaped curve in treated hypertensive patients with increased cardiovascular risk: the VALUE trial. Blood Press 25:83\u201392","journal-title":"Blood Press"},{"key":"97_CR24","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","volume":"360","author":"S Lewington","year":"2002","unstructured":"Lewington S, Clarke R, Qizilbash N, Prospective Studies Collaboration et al (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360:1903\u20131913","journal-title":"Lancet"},{"key":"97_CR25","first-page":"865","volume":"8","author":"O Lewis","year":"1994","unstructured":"Lewis O (1994) Stephen Hales and the measurement of blood pressure. J Hum Hypertens 8:865\u2013871","journal-title":"J Hum Hypertens"},{"key":"97_CR26","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR et al (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patient with nephropathy due to type 2 diabetes. N Engl J Med 345:851\u2013860","journal-title":"N Engl J Med"},{"key":"97_CR27","doi-asserted-by":"publisher","unstructured":"Lonn EM, Bosch J, Lopez\u2011Jaramillo P, et al. for the HOPE-3 Investigators (2016) Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. doi:\n                    10.1056\/NEJMoa1600175\n                    \n                  . [Epub ahead of print]","DOI":"10.1056\/NEJMoa1600175"},{"key":"97_CR28","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1097\/HJH.0b013e328333146d","volume":"27","author":"G Mancia","year":"2009","unstructured":"Mancia G, Laurent S, Agabiti-Rosei E et al (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 27:2121\u20132158","journal-title":"J Hypertens"},{"key":"97_CR29","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1093\/eurheartj\/ehv633","volume":"37","author":"G Mancia","year":"2016","unstructured":"Mancia G, Kjeldsen SE, Zappe DH et al (2016) Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial. Eur Heart J 37:955\u2013964","journal-title":"Eur Heart J"},{"key":"97_CR30","doi-asserted-by":"publisher","first-page":"884","DOI":"10.7326\/0003-4819-144-12-200606200-00005","volume":"144","author":"F Messerli","year":"2006","unstructured":"Messerli F, Mancia G, Conti R et al (2006) Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 144:884\u2013893","journal-title":"Ann Intern Med"},{"key":"97_CR31","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1093\/fampra\/cmr113","volume":"29","author":"MG Myers","year":"2012","unstructured":"Myers MG, Godwin M, Dawes M et al (2012) Conventional versus automated measurement of blood pressure in the office (CAMBO) trial. Fam Pract 29:376\u2013382","journal-title":"Fam Pract"},{"key":"97_CR32","unstructured":"National Heart, Lung, and Blood Institute (2015) Landmark NIH study shows intensive blood pressure management may save lives. Available from \n                    http:\/\/www.nhlbi.nih.gov\/news\/pressreleases\/2015\/landmark-nih-study-showsintensive-blood-pressure-management-may-save-lives.webpage\n                    \n                  . Accessed 11 Sept 2015"},{"key":"97_CR33","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/archinte.1992.00400130082009","volume":"152","author":"JD Neaton","year":"1992","unstructured":"Neaton JD, Wentworth D (1992) Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316 099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 152:56\u201364","journal-title":"Arch Intern Med"},{"key":"97_CR34","unstructured":"New York Times (2015) Lower blood pressure guidelines could be \u201clifesaving\u201d, federal study says. Available from \n                    http:\/\/www.nytimes.com\/2015\/09\/12\/health\/bloodpressure-study.html\n                    \n                  . Webpage accessed 8 Oct 2015"},{"key":"97_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2016.04.018","author":"PM Nilsson","year":"2016","unstructured":"Nilsson PM (2016) Blood pressure strategies and goals in elderly patients with hypertension. Exp Gerontol. doi:\n                    10.1016\/j.exger.2016.04.018\n                    \n                   [Epub ahead of print]","journal-title":"Exp Gerontol"},{"key":"97_CR36","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1056\/NEJMe1513301","volume":"373","author":"V Perkovic","year":"2015","unstructured":"Perkovic V, Rodgers A (2015) Redefining blood-pressure targets \u2014 SPRINT starts the marathon. N Engl J Med 373:2175\u20132178","journal-title":"N Engl J Med"},{"key":"97_CR37","doi-asserted-by":"publisher","first-page":"754","DOI":"10.7326\/0003-4819-123-10-199511150-00003","volume":"123","author":"JC Peterson","year":"1995","unstructured":"Peterson JC, Adler S, Burkart JM et al (1995) Blood pressure control, proteinuria and the progression of renal disease. Ann Intern Med 123:754\u2013762","journal-title":"Ann Intern Med"},{"key":"97_CR38","doi-asserted-by":"publisher","unstructured":"Pohl MA, Blumenthal S, Cordonnier DJ, et al. for the Collaborative Study Group (2005) Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the Irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol 16:3027\u20133037","DOI":"10.1681\/ASN.2004110919"},{"key":"97_CR39","first-page":"1","volume-title":"The hypertensive patient","author":"G Rose","year":"1980","unstructured":"Rose G (1980) Epidemiology. In: Marshall AJ, Barrett DW (eds) The hypertensive patient. Pitman Medical, Kent, pp 1\u201321"},{"key":"97_CR40","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(05)71082-5","volume":"365","author":"P Ruggenenti","year":"2005","unstructured":"Ruggenenti P, Perna A, Loriga G et al (2005) Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre randomized controlled trial. Lancet 365:939\u2013946","journal-title":"Lancet"},{"key":"97_CR41","doi-asserted-by":"publisher","unstructured":"Schrier RW, Abebe KZ, Perron RD, et al. for the HALT-PKD Trial Investigators (2014) Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med 371:2255\u20132266","DOI":"10.1056\/NEJMoa1402685"},{"key":"97_CR42","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1161\/01.CIR.0000160923.04524.5B","volume":"111","author":"R Sega","year":"2005","unstructured":"Sega R, Facchetti R, Bombelli M et al (2005) Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 111:1777\u20131783","journal-title":"Circulation"},{"key":"97_CR43","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr","year":"2015","unstructured":"SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK et al (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373:2103\u20132116","journal-title":"N Engl J Med"},{"key":"97_CR44","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.02.045","author":"SJ Taler","year":"2016","unstructured":"Taler SJ (2016) How does SPRINT (Systolic Blood Pressure Intervention Trial) direct hypertension treatment targets for CKD? Am J Kidney Dis. doi:\n                    10.1053\/j.ajkd.2016.02.045\n                    \n                  . [Epub ahead of print]","journal-title":"Am J Kidney Dis"},{"key":"97_CR45","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","volume":"31","author":"Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology","year":"2013","unstructured":"Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology (2013) 2013 ESH\/ESC practice Guidelines for the management of arterial hypertension. J Hypertens 31:1281\u20131357","journal-title":"J Hypertens"},{"key":"97_CR46","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0140-6736(13)60852-1","volume":"382","author":"The SPS3 Study Group","year":"2013","unstructured":"The SPS3 Study Group (2013) Effects of blood pressure targets in patients with recent lacunar strokes. Lancet 382:507\u2013515","journal-title":"Lancet"},{"key":"97_CR47","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3949\/ccjm.83a.15175","volume":"83","author":"G Thoma","year":"2016","unstructured":"Thoma G, Nally JV, Pohl MA (2016) Interpreting SPRINT: how low should you go? Cleve Clin J Med 83:187\u2013195","journal-title":"Cleve Clin J Med"},{"key":"97_CR48","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1097\/HJH.0000000000000379","volume":"32","author":"C Thomopoulosa","year":"2014","unstructured":"Thomopoulosa C, Parati G, Zanchetti A (2014) Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels \u2013 overview and meta-analyses of randomized trials. J Hypertens 32:2296\u20132304","journal-title":"J Hypertens"},{"key":"97_CR49","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1056\/NEJM199903043400902","volume":"340","author":"J Tuomilehto","year":"1999","unstructured":"Tuomilehto J, Rastenyte D, Birkenhager WH et al (1999) Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic hypertension in Europe Trial Investigators. N Engl J Med 340:677\u2013684","journal-title":"N Engl J Med"},{"key":"97_CR50","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1056\/NEJMoa003417","volume":"345","author":"RS Vasan","year":"2001","unstructured":"Vasan RS, Larson MG, Leip EP et al (2001) Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 345:1291\u20131297","journal-title":"N Engl J Med"},{"key":"97_CR51","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1161\/HYPERTENSIONAHA.114.04310","volume":"65","author":"P Verdecchia","year":"2015","unstructured":"Verdecchia P, Reboldi G, Angeli F et al (2015) Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary heart disease. Hypertension 65:108\u2013114","journal-title":"Hypertension"},{"key":"97_CR52","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0140-6736(15)00805-3","volume":"387","author":"X Xie","year":"2016","unstructured":"Xie X, Atkins E, Lv J et al (2016) Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 387:435\u2013443","journal-title":"Lancet"},{"key":"97_CR53","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1097\/HJH.0b013e32832aa6b5","volume":"27","author":"A Zanchetti","year":"2009","unstructured":"Zanchetti A, Grassi G, Mancia G (2009) When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 27:923\u2013934","journal-title":"J Hypertens"},{"key":"97_CR54","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/HJH.0000000000000853","volume":"34","author":"A Zanchetti","year":"2016","unstructured":"Zanchetti A, Liu L, Mancia G, ESH-CHL-SHOT trialinvestigators et al (2016) Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke. J Hypertens 34:393\u20136","journal-title":"J Hypertens"}],"container-title":["Advances in Experimental Medicine and Biology","Hypertension: from basic research to clinical practice"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/5584_2016_97","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T17:17:23Z","timestamp":1494350243000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/5584_2016_97"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"ISBN":["9783319442501","9783319442518"],"references-count":55,"URL":"https:\/\/doi.org\/10.1007\/5584_2016_97","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}